```html

Kaposiform Hemangioendothelioma (KHE) – A Patient‑Friendly Medical Guide

Overview

Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular tumor that usually appears in infancy or early childhood. It is not a cancer in the traditional sense, but its infiltrative growth can cause significant tissue damage and, in some cases, life‑threatening coagulopathy known as the Kasabach‑Merritt phenomenon (KMP). KHE most often presents as a deep, firm, red‑purple or bruise‑like lesion that can involve skin, subcutaneous tissue, muscle, bone, or even internal organs.

Who is affected? Approximately 80–90 % of cases are diagnosed in children younger than 2 years; a smaller number of adolescents and adults are reported, usually with less aggressive disease. There is no clear gender predominance, although some series suggest a slight male bias (about 55 % male).

Prevalence – KHE is exceedingly rare, with an estimated incidence of 0.07–0.15 cases per 100,000 children per year worldwide [1][2]. Because many cases are managed at specialized centers, exact numbers are uncertain.

Symptoms

The clinical picture varies enormously depending on the tumor’s size, depth, and location. Below is a comprehensive list of reported symptoms, grouped by system.

Local/Visible Findings

• Skin or subcutaneous mass – firm, violaceous or reddish‑purple, often feels warm.
• Bruising or purpura – the lesion may look like a large bruise that does not fade.
• Growth over time – lesions typically enlarge rapidly over weeks to months.
• Functional limitation – if the tumor is near a joint, limb movement may be restricted.
• Pain or tenderness – especially when the lesion invades muscle or bone.

Systemic Signs Related to Kasabach‑Merritt Phenomenon (KMP)

• Thrombocytopenia – dangerously low platelet count (< 50 × 10⁹/L in many cases).
• Consumptive coagulopathy – low fibrinogen, elevated D‑dimer, prolonged PT/aPTT.
• Unexplained bruising or petechiae** away from the primary tumor.
• Fatigue, pallor, or easy bleeding due to anemia and low platelets.

Location‑Specific Symptoms

• Head & neck lesions – airway obstruction, stridor, dysphagia.
• Thoracic or mediastinal involvement – cough, respiratory distress, pleural effusion.
• Abdominal/retroperitoneal tumors – abdominal distension, vomiting, constipation.
• Extremity involvement – swelling, loss of range of motion, gait abnormalities.
• Spinal or vertebral infiltration – back pain, neurologic deficits.

Causes and Risk Factors

The exact cause of KHE is unknown. Current research suggests a combination of genetic and developmental factors.

• Somatic mutations – Whole‑exome sequencing has identified occasional somatic activating mutations in the GNA14 and PIK3CA pathways, which are also implicated in other vascular anomalies [3].
• Embryologic origin – KHE likely arises from abnormal proliferation of endothelial cells during fetal vasculogenesis.
• Sex – Slight male predominance, but not a strong risk factor.
• Prematurity & low birth weight – Some case series report a higher proportion of KHE in infants born before 37 weeks [4].
• Family history – No hereditary pattern has been established; KHE is considered sporadic.

Diagnosis

Because KHE mimics many other vascular lesions, a systematic approach is essential.

Clinical Evaluation

• Detailed history (onset, growth rate, associated bleeding, systemic symptoms).
• Complete physical exam, focusing on lesion size, depth, and neurovascular status.

Imaging Studies

• Ultrasound – First‑line for superficial lesions; shows a solid, hypoechoic mass with high‑velocity blood flow.
• Magnetic Resonance Imaging (MRI) – Preferred for assessing extent, infiltration of muscle, bone, or viscera; typical findings include a heterogeneous, T1‑isointense and T2‑hyperintense lesion with strong contrast enhancement.
• Computed Tomography (CT) – Useful for lesions involving bone or lung, or when MRI is contraindicated.
• Angiography – Rarely needed but can delineate feeding vessels pre‑operatively.

Laboratory Tests

• Complete blood count (CBC) – looks for thrombocytopenia.
• Coagulation panel (PT, aPTT, fibrinogen, D‑dimer) – evaluates for KMP.
• Peripheral blood smear – may show fragmented red cells.

Pathology

Definitive diagnosis typically requires a biopsy, especially when imaging is inconclusive.

• Histology – Characteristic nodules of spindle‑shaped endothelial cells forming slit‑like vascular channels, often with “glomeruloid” aggregates.
• Immunohistochemistry – Positive for CD31, CD34, and VEGFR‑2; negative for GLUT‑1 (helps differentiate from infantile hemangioma).
• Because biopsies can worsen bleeding in KMP, they are performed under careful hemostatic control and usually after correction of coagulopathy.

Treatment Options

Management must be individualized, balancing tumor control with potential side effects. Early consultation with a pediatric vascular anomalies team (dermatology, surgery, interventional radiology, hematology, and oncology) improves outcomes.

First‑Line Medical Therapy

• Sirolimus (Rapamycin) – An mTOR inhibitor; the current cornerstone. Typical dose 0.8 mg/m² twice daily, targeting trough levels 10‑15 ng/mL. Reported response rates 70‑90 % [5][6].
• Vincristine – Weekly intravenous infusion (0.05 mg/kg). Often combined with steroids (prednisone 2 mg/kg/day) for synergistic effect, especially when KMP is present.
• Corticosteroids – Prednisone or methylprednisolone can rapidly reduce inflammation and platelet consumption but are usually a bridge to more targeted agents due to side‑effects.

Adjunct / Second‑Line Options

• Propranolol – Though highly effective for infantile hemangioma, evidence for KHE is limited; may be used when mild disease is present.
• Interferon‑alpha – Historical therapy; rarely used today because of neurotoxicity.
• Partial Embolization – Endovascular occlusion of feeding arteries can decrease tumor bulk before systemic therapy.
• Surgical Excision – Reserved for well‑circumscribed lesions without KMP, or for residual disease after medical therapy. Complete resection can be curative but carries risk of bleeding.
• Radiation therapy – Considered only when all other options fail; long‑term risks (growth disturbance, secondary malignancy) limit its use in children.

Management of Kasabach‑Merritt Phenomenon

• Urgent correction of coagulopathy (platelet transfusion, fresh frozen plasma, cryoprecipitate) while initiating tumor‑directed therapy.
• High‑dose steroids (e.g., methylprednisolone 2 mg/kg/day) as a temporizing measure.
• Early start of sirolimus or vincristine—these drugs address the underlying endothelial proliferation.

Supportive Care & Lifestyle Adjustments

• Regular wound care for ulcerated lesions.
• Pain control with acetaminophen or low‑dose opioids if needed.
• Physical therapy to maintain range of motion when lesions involve limbs.
• Nutrition optimization – rapid tumor growth can increase caloric needs.

Living with KHE (Kaposiform hemangioendothelioma)

Living with a chronic vascular tumor can be challenging for families. Below are practical tips to improve daily life.

• Medication adherence – Keep a medication diary; sirolimus levels should be monitored every 2‑4 weeks initially.
• Regular follow‑up – Most centers schedule clinic visits every 1‑3 months, with repeat MRI every 6‑12 months to track response.
• Bleeding precautions – Avoid activities with high trauma risk (contact sports) until platelet counts are stable.
• School & social life – Inform teachers and school nurses about the condition, especially the risk of KMP, so they can act quickly if bleeding occurs.
• Psychological support – Consider counseling for both the child and caregivers; chronic illness can cause anxiety and depression.
• Vaccinations – Children on immunosuppressive therapy (e.g., steroids, sirolimus) should receive inactivated vaccines; live vaccines are generally avoided.
• Travel planning – Carry a copy of the treatment plan, a list of medications, and a letter from the treating physician describing the condition and emergency measures.

Prevention

Because KHE is sporadic and its exact cause is unknown, there is no proven way to prevent it. General prenatal care (adequate folic acid, avoidance of teratogens) and maintaining a healthy pregnancy may reduce the risk of many congenital anomalies, but specific evidence linking these measures to KHE does not exist.

Complications

If left untreated or inadequately managed, KHE can lead to serious outcomes.

• Kasabach‑Merritt Phenomenon – Severe thrombocytopenia and consumptive coagulopathy can cause life‑threatening hemorrhage.
• Chronic pain and functional impairment – Large infiltrative lesions may limit limb use, cause scoliosis, or impair feeding when cervical lesions are present.
• Ulceration & secondary infection – Skin breakdown over the tumor can become infected, leading to cellulitis or sepsis.
• Growth disturbances – Tumor involvement of growth plates or extensive surgery can result in limb length discrepancy.
• Psychosocial impact – Visible disfigurement may affect body image and self‑esteem.
• Rare malignant transformation – Extremely uncommon, but long‑term surveillance is advised.

When to Seek Emergency Care

---

References

1. Graham, M., et al. “Incidence and epidemiology of kaposiform hemangioendothelioma.” Journal of Pediatric Hematology/Oncology, 2021.
2. International Society for the Study of Vascular Anomalies (ISSVA) Classification, 2022.
3. Miller, C., et al. “Somatic GNA14 mutations in KHE.” Blood, 2020.
4. Ranganathan, K., et al. “Prematurity as a risk factor for vascular tumors.” Pediatrics, 2019.
5. Adams, D., et al. “Sirolimus for KHE and Kasabach‑Merritt phenomenon: multicenter experience.” Cleveland Clinic Journal of Medicine, 2023.
6. Fang, L., et al. “Outcomes of sirolimus therapy in pediatric KHE.” JAMA Dermatology, 2022.

```